Welcome to my personal webpage

Also visit my LinkedIn profile.

Below you can find, amongst other things, some research results from my SMALL paper.

Further details are on the SPECIAL WEBPAGE which was created from my Ph.D. supervisor Prof. Dr. Jörg Huwyler.

All results and images were created together with the Pharmaceutical Technology group during my time as a Ph.D. candidate.

Dr. Emre Çörek

Dr. Emre Çörek

Regulatory Toxicologist

Swiss Centre for Applied Human Toxicology


I graduated from the Julius-Maximilians-University of Wuerzburg in Germany with a Bachelor’s degree in “Biology” in March 2013. My Bachelor’s thesis, I carried out for six months at the University Hospital of Wuerzburg about the breast cancer radiosensitizing agent “NVP-BEZ235 (Dactolisib)". The title of my Bachelor`s thesis was “Modulation der Strahlenempfindlichkeit humaner Mammakarzinom-Zelllinien mittels des neuartigen dualen PI3K- und mTOR-Inhibitors NVP-BEZ235. Einfluss von Hypoxie”.

In July 2015, I graduated with a Master’s degree from the University of Basel in Switzerland in “Toxicology”. My Master’s thesis I accomplished for 10 months at Novartis AG in Basel in Preclinical safety about the renal biomarker Kidney injury molecule-1 (KIM-1). The title of my thesis was “Spatial and temporal patterns of KIM-1 induction in toxic kidney injury in rats”.

In June 2016, after a one year break with travelling, I joined the research group of Prof. Dr. Jörg Huwyler in Pharmaceutical Technology at the University of Basel as a Ph.D. candidate. My research was focused on nanoparticles for drug delivery and imaging/theranostics. At the same time I was also involved in the EU Horizon 2020 project called “NanoREG II” for development and implementation of nanoparticle grouping and Safe-by-design approaches within regulatory frameworks together with the Swiss Centre for Applied Human Toxicology (SCAHT). In May 2020, I finished my Ph.D. (Dr. phil. des.) and since September 2020 I am working as a regulatory toxicologist at the Swiss Centre for Applied Human Toxicology (SCAHT) on a project about “succinate dehydrogenase inhibitors (SDHIs)".


  • Toxicology
  • Nanoparticles
  • Drug Delivery
  • Imaging
  • Cancer Biology
  • Regulatory Toxicology


  • Ph.D. in Pharmaceutical Sciences, May, 2020

    University of Basel, Switzerland

  • M.Sc. in Toxicology, 2015

    University of Basel, Switzerland

  • B.Sc. in Biology, 2013

    Julius-Maximilians-University of Wuerzburg, Germany


Here you can find the latest news about me and my work

Small Journal Cover Image

My publication was chosen as the cover image in Small Volume 16, Issue 31.

Laborpraxis news article about my Small publication

The news article is available in German.

MyScience news article about my Small publication

The news article is available in German, English, and French.

University of Basel news article about my Small publication

The news article is available in German and English.

Webpage about our zebrafish findings published in SMALL

The webpage was created from my Ph.D. supervisor Prof. Dr. Jörg Huwyler from the Pharmaceutical Technology group of the University of Basel.


Here you can find my latest publications

Shedding Light on Metal‐Based Nanoparticles in Zebrafish by Computed Tomography with Micrometer Resolution

Metal‐based nanoparticles are clinically used for diagnostic and therapeutic applications. After parenteral administration, they will distribute throughout different organs. Quantification of their distribution within tissues in the 3D space, however, remains a challenge owing to the small particle diameter. In this study, synchrotron radiation‐based hard X‐ray tomography (SRμCT) in absorption and phase contrast modes is evaluated for the localization of superparamagnetic iron oxide nanoparticles (SPIONs) in soft tissues based on their electron density and X‐ray attenuation. Biodistribution of SPIONs is studied using zebrafish embryos as a vertebrate screening model. This label‐free approach gives rise to an isotropic, 3D, direct space visualization of the entire 2.5 mm‐long animal with a spatial resolution of around 2 µm. High resolution image stacks are available on a dedicated internet page https://zebrafish.pharma‐te.ch. X‐ray tomography is combined with physico‐chemical characterization and cellular uptake studies to confirm the safety and effectiveness of protective SPION coatings. It is demonstrated that SRμCT provides unprecedented insights into the zebrafish embryo anatomy and tissue distribution of label‐free metal oxide nanoparticles.

Preclinical hazard evaluation strategy for nanomedicines

The increasing nanomedicine usage has raised concerns about their possible impact on human health. Present evaluation strategies for nanomaterials rely on a case-by-case hazard assessment. They take into account material properties, biological interactions, and toxicological responses. Authorities have also emphasized that exposure route and intended use should be considered in the safety assessment of nanotherapeutics. In contrast to an individual assessment of nanomaterial hazards, we propose in the present work a novel and unique evaluation strategy designed to uncover potential adverse effects of such materials. We specifically focus on spherical engineered nanoparticles used as parenterally administered nanomedicines. Standardized assay protocols from the US Nanotechnology Characterization Laboratory as well as the EU Nanomedicine Characterisation Laboratory can be used for experimental data generation. We focus on both cellular uptake and intracellular persistence as main indicators for nanoparticle hazard potentials. Based on existing regulatory specifications defined by authorities such as the European Medicines Agency and the United States Food and Drug Administration, we provide a robust framework for application-oriented classification paired with intuitive decision making. The Hazard Evaluation Strategy (HES) for injectable nanoparticles is a three-tiered concept covering physicochemical characterization, nanoparticle (bio)interactions, and hazard assessment. It is cost-effective and can assist in the design and optimization of nanoparticles intended for therapeutic use. Furthermore, this concept is designed to be adaptable for alternative exposure and application scenarios. To the knowledge of the authors, the HES is unique in its methodology based on exclusion criteria. It is the first hazard evaluation strategy designed for nanotherapeutics.

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions

In the present study, we assessed, if the novel dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235 radiosensitizes triple negative (TN) MDA-MB-231 and estrogen receptor (ER) positive MCF-7 cells to ionizing radiation under various oxygen conditions, simulating different microenvironments as occurring in the majority of breast cancers (BCs). Irradiation (IR) of BC cells cultivated in hypoxic conditions revealed increased radioresistance compared to normoxic controls. Treatment with NVP-BEZ235 completely circumvented this hypoxia-induced effects and radiosensitized normoxic, reoxygenated, and hypoxic cells to similar extents. Furthermore, NVP-BEZ235 treatment suppressed HIF-1α expression and PI3K/mTOR signaling, induced autophagy, and caused protracted DNA damage repair in both cell lines in all tested oxygen conditions. Moreover, after incubation with NVP-BEZ235, MCF-7 cells revealed depletion of phospho-AKT and considerable signs of apoptosis, which were significantly enhanced by radiation. Our findings clearly demonstrate that NVP-BEZ235 has a clinical relevant potential as a radiosensitizer in BC treatment.


You can also use my LinkedIn profile to get in touch with me.